116 related articles for article (PubMed ID: 38363069)
21. PD-L1/TLR7 dual-targeting nanobody-drug conjugate mediates potent tumor regression via elevating tumor immunogenicity in a host-expressed PD-L1 bias-dependent way.
Yu X; Long Y; Chen B; Tong Y; Shan M; Jia X; Hu C; Liu M; Zhou J; Tang F; Lu H; Chen R; Xu P; Huang W; Ren J; Wan Y; Sun J; Li J; Jin G; Gong L
J Immunother Cancer; 2022 Oct; 10(10):. PubMed ID: 36253000
[TBL] [Abstract][Full Text] [Related]
22. Structure-Based Design of Highly Potent Toll-like Receptor 7/8 Dual Agonists for Cancer Immunotherapy.
Wang Z; Gao Y; He L; Sun S; Xia T; Hu L; Yao L; Wang L; Li D; Shi H; Liao X
J Med Chem; 2021 Jun; 64(11):7507-7532. PubMed ID: 34048243
[TBL] [Abstract][Full Text] [Related]
23. Imidazoquinolines with improved pharmacokinetic properties induce a high IFNα to TNFα ratio
Keppler M; Straß S; Geiger S; Fischer T; Späth N; Weinstein T; Schwamborn A; Guezguez J; Guse JH; Laufer S; Burnet M
Front Immunol; 2023; 14():1168252. PubMed ID: 37409123
[TBL] [Abstract][Full Text] [Related]
24. A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist.
Chi H; Hao Y; Wang X; Tang L; Deng Y; Chen X; Gao F; Sha O; Jin G
Cells; 2022 Jun; 11(13):. PubMed ID: 35805071
[TBL] [Abstract][Full Text] [Related]
25.
Yang BY; Cheng YG; Liu Y; Liu Y; Tan JY; Guan W; Guo S; Kuang HX
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181689
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of TLR4- and -7-induced NF kappa B1 p105-TPL2-ERK pathway to TNF-receptor-associated-factor-6 revealed by RNAi in mouse macrophages.
Loniewski KJ; Patial S; Parameswaran N
Mol Immunol; 2007 Jul; 44(15):3715-23. PubMed ID: 17507094
[TBL] [Abstract][Full Text] [Related]
27. Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.
Gunzer M; Riemann H; Basoglu Y; Hillmer A; Weishaupt C; Balkow S; Benninghoff B; Ernst B; Steinert M; Scholzen T; Sunderkötter C; Grabbe S
Blood; 2005 Oct; 106(7):2424-32. PubMed ID: 15976181
[TBL] [Abstract][Full Text] [Related]
28. A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Auderset F; Belnoue E; Mastelic-Gavillet B; Lambert PH; Siegrist CA
Front Immunol; 2020; 11():580974. PubMed ID: 33262759
[TBL] [Abstract][Full Text] [Related]
29. Cancer immunotherapeutic potential of novel small molecule TLR7 and TLR8 agonists.
Hamm S; Rath S; Michel S; Baumgartner R
J Immunotoxicol; 2009 Dec; 6(4):257-65. PubMed ID: 19848448
[TBL] [Abstract][Full Text] [Related]
30. Extracellular HSP90α Induces MyD88-IRAK Complex-Associated IKKα/β-NF-κB/IRF3 and JAK2/TYK2-STAT-3 Signaling in Macrophages for Tumor-Promoting M2-Polarization.
Fan CS; Chen CC; Chen LL; Chua KV; Hung HC; Hsu JT; Huang TS
Cells; 2022 Jan; 11(2):. PubMed ID: 35053345
[TBL] [Abstract][Full Text] [Related]
31. Chitosan-Poly(Acrylic Acid) Nanoparticles Loaded with R848 and MnCl
Liu X; Xu Y; Yin L; Hou Y; Zhao S
Int J Nanomedicine; 2021; 16():5675-5692. PubMed ID: 34456564
[TBL] [Abstract][Full Text] [Related]
32. Nuclear factor kappaB (NF-kappaB) activation primes cells to a pro-inflammatory polarized response to a Toll-like receptor 7 (TLR7) agonist.
Lee J; Hayashi M; Lo JF; Fearns C; Chu WM; Luo Y; Xiang R; Chuang TH
Biochem J; 2009 Jun; 421(2):301-10. PubMed ID: 19426145
[TBL] [Abstract][Full Text] [Related]
33. The small antitumoral immune response modifier imiquimod interacts with adenosine receptor signaling in a TLR7- and TLR8-independent fashion.
Schön MP; Schön M; Klotz KN
J Invest Dermatol; 2006 Jun; 126(6):1338-47. PubMed ID: 16575388
[TBL] [Abstract][Full Text] [Related]
34. Lyophilizable and Multifaceted Toll-like Receptor 7/8 Agonist-Loaded Nanoemulsion for the Reprogramming of Tumor Microenvironments and Enhanced Cancer Immunotherapy.
Kim SY; Kim S; Kim JE; Lee SN; Shin IW; Shin HS; Jin SM; Noh YW; Kang YJ; Kim YS; Kang TH; Park YM; Lim YT
ACS Nano; 2019 Nov; 13(11):12671-12686. PubMed ID: 31589013
[TBL] [Abstract][Full Text] [Related]
35. Activation of NF-κB via endosomal Toll-like receptor 7 (TLR7) or TLR9 suppresses murine herpesvirus 68 reactivation.
Haas F; Yamauchi K; Murat M; Bernasconi M; Yamanaka N; Speck RF; Nadal D
J Virol; 2014 Sep; 88(17):10002-12. PubMed ID: 24942583
[TBL] [Abstract][Full Text] [Related]
36. TLR7 and TLR8 Differentially Activate the IRF and NF-κB Pathways in Specific Cell Types to Promote Inflammation.
Bender AT; Tzvetkov E; Pereira A; Wu Y; Kasar S; Przetak MM; Vlach J; Niewold TB; Jensen MA; Okitsu SL
Immunohorizons; 2020 Feb; 4(2):93-107. PubMed ID: 32086319
[TBL] [Abstract][Full Text] [Related]
37. Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.
Meneveau MO; Petroni GR; Salerno EP; Lynch KT; Smolkin M; Woodson E; Chianese-Bullock KA; Olson WC; Deacon D; Patterson JW; Grosh WW; Slingluff CL
J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34035112
[TBL] [Abstract][Full Text] [Related]
38. [Effect of shufeng xuanfei recipe and jiebiao qingli recipe on mRNA and protein expressions of TLR7, MyD88, and NF-kappaB in mice infected with influenza virus].
Liu Q; Gu LG; Lu NN; Zhou XP; Wu J; Qiu ZJ; Zhang HC; Chao EX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2013 Sep; 33(9):1256-60. PubMed ID: 24273985
[TBL] [Abstract][Full Text] [Related]
39. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod.
Gibson SJ; Lindh JM; Riter TR; Gleason RM; Rogers LM; Fuller AE; Oesterich JL; Gorden KB; Qiu X; McKane SW; Noelle RJ; Miller RL; Kedl RM; Fitzgerald-Bocarsly P; Tomai MA; Vasilakos JP
Cell Immunol; 2002; 218(1-2):74-86. PubMed ID: 12470615
[TBL] [Abstract][Full Text] [Related]
40. Cutting edge: activation of murine TLR8 by a combination of imidazoquinoline immune response modifiers and polyT oligodeoxynucleotides.
Gorden KK; Qiu XX; Binsfeld CC; Vasilakos JP; Alkan SS
J Immunol; 2006 Nov; 177(10):6584-7. PubMed ID: 17082568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
